« Back
Home /
Anti-SARS-CoV Spike (15aa - Intermediate Domain) - 0.1 mg

Anti-SARS-CoV Spike (15aa - Intermediate Domain) - 0.1 mg

Item no.	LEIN-S543-0.1mg
Manufacturer	Leinco Technologies
Amount	0.1 mg
Quantity options	0.1 mg 20 ug
Category	Antibodies ELISA Primary Antibodies Immunostaining
Type	Antibody Primary
Applications	ELISA
Specific against	Virus
Host	Rabbit
NCBI	1489668
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Shipping Condition	Room temperature
Available
Manufacturer - Applications	Quality Tested by Leinco ELISA
Manufacturer - Category	Primary Monoclonal Antibodies>Infectious Diseases\|SARS-CoV-2
Manufacturer - Targets	SARS Spike
Country of Origin	USA
Shipping Temperature	Next Day Ambient
Storage Conditions	This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Product Description	A coronavirus, SARS (Severe Acute Respiratory Syndrome), was first identified 2002-2003. Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS can be mediated by the binding of the viral spike protein, a glycosylated protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.
Background	A coronavirus, SARS (Severe Acute Respiratory Syndrome), was first identified 2002-2003. Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS can be mediated by the binding of the viral spike protein, a glycosylated protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.
PubMed	SARS Spike
Manufacturer - Research Area	COVID-19, Infectious Disease, Seasonal and Respiratory Infections, Viral, IVD Raw Material
Manufacturer - Specificity	Rabbit Anti-Severe Acute Respiratory Syndrome Spike (SARS-CoV Spike) recognizes an epitope in the intermediate domain of SARS Spike. This polyclonal antibody was purified using affinity chromatography.
RRID	AB_2831781
Concentration	0.5 mg/ml
Formulation	This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen	Anti-SARS-CoV Spike antibody was raised against a peptide corresponding to 15 amino acids near the center of SARS-CoV Spike glycoprotein. The immunogen is located within amino acids 650-700 of SARS-CoV Spike.
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords	Polyclonal Antibody, SARS Spike, Human, Anti-Severe Acute Respiratory Syndrome Spike (Intermediate Domain 3) (SARS Spike), SARS Spike Antibody, E2, Spike glycoprotein, E2, S glycoprotein, COVID-19, SAR-CoV

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

LEIN-S543-0.1mg-safety-datasheet.pdf